Dawn I Velligan1, David Roberts2, Jim Mintz2, Natalie Maples3, Xueying Li2, Elisa Medellin2, Matt Brown2. 1. University of Texas Health Science Center at San Antonio, Department of Psychiatry, M.S. # 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, United States. Electronic address: velligand@uthscsa.edu. 2. University of Texas Health Science Center at San Antonio, Department of Psychiatry, M.S. # 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, United States. 3. University of Texas Health Science Center at San Antonio, Department of Psychiatry, M.S. # 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, United States; University of Texas School of Public Health, Center for Health Promotion & Prevention Research, M.S. # 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, United States.
Abstract
INTRODUCTION: Among individuals with schizophrenia, those who have persistent and clinically significant negative symptoms (PNS) have the poorest functional outcomes and quality of life. The NIMH-MATRICS Consensus Statement indicated that these symptoms represent an unmet therapeutic need for large numbers of individuals with schizophrenia. No psychosocial treatment model addresses the entire constellation of PNS. METHOD:51 patients with PNS were randomized into one of two groups for a period of 9 months: 1) MOtiVation and Enhancement (MOVE) or 2) treatment as usual. MOVE is a home based, manual-driven, multi-modal treatment that employs a number of cognitive and behavioral principles to address the broad range of factors contributing to PNS and their functional consequences. The components of MOVE include: Environmental supports to prompt initiation and persistence, in-vivo skills training to ameliorate deficits and encourage interaction, cognitive behavioral techniques to address self-defeating attitudes, in-vivo training in emotional processing to address affective blunting and problems in identifying emotions, and specific techniques to address the deficits in anticipatory pleasure. Patients were assessed at baseline and each 3 months with multiple measures of negative symptoms. RESULTS: Repeated measures analyses of variance for mixed models indicated significant Group by Time effects for the Negative Symptom Assessment (NSA; p<.02) and the Clinical Assessment Interview for Negative Symptoms (CAINS; p<.04). Group differences were not significant until 9 months of treatment and were not significant for the Brief Negative Symptom Scale (BNSS). CONCLUSION: Further investigation of a comprehensive treatment for PNS, such as MOVE, is warranted. Published by Elsevier B.V.
RCT Entities:
INTRODUCTION: Among individuals with schizophrenia, those who have persistent and clinically significant negative symptoms (PNS) have the poorest functional outcomes and quality of life. The NIMH-MATRICS Consensus Statement indicated that these symptoms represent an unmet therapeutic need for large numbers of individuals with schizophrenia. No psychosocial treatment model addresses the entire constellation of PNS. METHOD: 51 patients with PNS were randomized into one of two groups for a period of 9 months: 1) MOtiVation and Enhancement (MOVE) or 2) treatment as usual. MOVE is a home based, manual-driven, multi-modal treatment that employs a number of cognitive and behavioral principles to address the broad range of factors contributing to PNS and their functional consequences. The components of MOVE include: Environmental supports to prompt initiation and persistence, in-vivo skills training to ameliorate deficits and encourage interaction, cognitive behavioral techniques to address self-defeating attitudes, in-vivo training in emotional processing to address affective blunting and problems in identifying emotions, and specific techniques to address the deficits in anticipatory pleasure. Patients were assessed at baseline and each 3 months with multiple measures of negative symptoms. RESULTS: Repeated measures analyses of variance for mixed models indicated significant Group by Time effects for the Negative Symptom Assessment (NSA; p<.02) and the Clinical Assessment Interview for Negative Symptoms (CAINS; p<.04). Group differences were not significant until 9 months of treatment and were not significant for the Brief Negative Symptom Scale (BNSS). CONCLUSION: Further investigation of a comprehensive treatment for PNS, such as MOVE, is warranted. Published by Elsevier B.V.
Entities:
Keywords:
Clinical Assessment Interview for Negative Symptoms; MOtiVation and Enhancement (MOVE) Training; Negative Symptom Assessment; Negative symptoms; Schizophrenia
Authors: Dawn I Velligan; Pamela M Diamond; Jim Mintz; Natalie Maples; Xueying Li; John Zeber; Larry Ereshefsky; Yui-Wing F Lam; Desiree Castillo; Alexander L Miller Journal: Schizophr Bull Date: 2007-10-10 Impact factor: 9.306
Authors: Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Brian Kirkpatrick; Gary D Hack; Erik Higginbottom; Daniel Hoffacker; Emilio Fernandez-Egea Journal: Schizophr Res Date: 2007-02-21 Impact factor: 4.939
Authors: Robert W Buchanan; Daniel C Javitt; Stephen R Marder; Nina R Schooler; James M Gold; Robert P McMahon; Uriel Heresco-Levy; William T Carpenter Journal: Am J Psychiatry Date: 2007-10 Impact factor: 18.112
Authors: Dawn I Velligan; Pamela M Diamond; Natalie J Maples; James Mintz; Xueying Li; David C Glahn; Alexander L Miller Journal: Schizophr Res Date: 2008-04-18 Impact factor: 4.939
Authors: Dawn I Velligan; Pamela Diamond; Janet Mueller; Xueying Li; Natalie Maples; Mei Wang; Alexander L Miller Journal: Psychiatry Res Date: 2009-06-11 Impact factor: 3.222
Authors: L Felice Reddy; William P Horan; Deanna M Barch; Robert W Buchanan; James M Gold; Stephen R Marder; Jonathan K Wynn; Jared Young; Michael F Green Journal: Schizophr Bull Date: 2018-10-17 Impact factor: 9.306
Authors: Eric Granholm; Elizabeth W Twamley; Zanjbeel Mahmood; Amber V Keller; Hannah C Lykins; Emma M Parrish; Michael L Thomas; Dimitri Perivoliotis; Jason L Holden Journal: Schizophr Bull Date: 2022-03-01 Impact factor: 7.348